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Aim: Probiotic bacteria administered directly after birth to preterm neonates may improve 
gastrointestinal function and may reduce the incidence of late-onset sepsis, which is a frequent 
complication in this group.
Purpose: The main objective of this study was to evaluate whether a new probiotic bacterial 
mixture of Lactobacillus rhamnosus KL53A and Bifidobacterium breve PB04 given to preterm, 
low-birth-weight neonates would influence composition of their gut microbiota and sepsis rates.
Patients and methods: This study was a multicenter, randomized, double-blind, placebo-
controlled trial conducted in clinical centers of neonatal care in Poland. A probiotic or placebo 
preparation was given twice daily to 181 preterm low-birth-weight neonates who were eligible 
for enteral feeding between July 2012 and July 2013. The probiotic was given to 90 neonates, 
while placebo was given to 91 neonates. The gut microbiota was monitored by microbiological 
analysis of stool samples. Sepsis episodes were detected on the basis of clinical and laboratory 
findings and confirmed by blood cultures.
Results: Tested probiotic administration resulted in continuous increase of the Lactobacil-
lus and Bifidobacterium counts in the gut microbiota. The applied tested strains successfully 
colonized the neonates gut since they were present in over 90% of stool samples, which was 
confirmed by molecular analysis. Regardless of the study group (probiotic or placebo), B. breve 
 colonization correlated with lower staphylococcal sepsis incidence, which was irrespective of 
whether  probiotics were given. No sepsis case caused by strains included in study probiotic 
was recorded.
Conclusion: Appropriately selected and characterized probiotic bacteria may be safely given 
to preterm neonates to normalize their distorted gut microbiota and may contribute to lower 
staphylococcal sepsis rates.
Keywords: probiotics, LBW neonates, staphylococcal sepsis, gut microbiota, Lactobacillus, 
Bifidobacterium
Introduction
Nosocomial infection rates in neonates vary from 6% to 50% depending on their weight 
and related immune system maturity. Bloodstream infections in very low-birth-weight 
(VLBW) and low-birth-weight (LBW) neonates are believed to be catheter related 
because critically ill infants require the delivery of nutrients and drugs over long 
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period of time. A disadvantage of long-term catheter use in 
neonates is that bloodstream infections (CR-BSIs) caused 
primarily by coagulase-negative staphylococci (CoNS), such 
as Staphylococcus epidermidis, are common and responsible 
for significant global morbidity in VLBW. In contrast, term 
infants are only rarely infected.1–3
Thus, it is commonly accepted that the skin insertion 
site and the catheter hub are the most important sources 
of catheter colonization. From the contaminated hub, the 
organisms may migrate along the surface of the catheter 
and enter the bloodstream, which cause late-onset sepsis 
(LOS). This view is based on in vitro studies demonstrating 
that CoNS and particularly S. epidermidis are extremely 
capable of adhering to plastic surfaces of the catheters and 
biofilm formation. In addition to intrinsically high resistance 
of bacteria contained in biofilms to antibiotics, methicillin-
resistant S. epidermidis clinical isolates (methicillin-resistant 
S. epidermidis [MRSE]) are widespread and complicates 
the treatment. Diagnosis of sepsis is confirmed by a posi-
tive culture of bacteria obtained from blood. More stringent 
measures include positive cultures from the catheter hub and 
a peripheral vessel.4,5
There are, however, reports on LOS were related not to 
catheter use but to translocation of bacteria from gut lumen to 
bloodstream due to increased intestinal permeability typical 
for premature neonates.6–8 Distortions in the establishment 
of normal gut microbiota with increased populations of 
commensal microbes that colonize the digestive tract might 
increase the risk of LOS via disruption of the mucosal bar-
rier with resultant translocation of luminal contents. Mai 
et al in their study based on matched case–control analysis 
identified microbiota differences in very premature infants 
with LOS.9 Consistent with many reports, CoNS was the 
most common microbe cultured from the blood of infants 
with LOS. Although they were not able to detect a differ-
ence in the abundance of CoNS in the stool samples of LOS 
and control infants, they detected a higher proportion of 
Firmicutes phylum (the phylum to which CoNS belongs) in 
LOS cases 2 weeks before diagnosis of sepsis. Stewart et al 
noticed earlier that preterm gut microbiota was characterized 
with the predominance of E. faecalis and CoNS as detected 
by cultures.10 Both bacterial taxa were found by molecular 
methods to be associated with LOS and necrotizing entero-
colitis (NEC).
Therefore, it is highly probable that at least a part of LOS 
cases treated in neonatal intensive care units (NICUs) may be 
related to translocation of commensal bacteria from gut due 
to impaired tight junctions in the mucosa. Such a mechanism 
may implicate a positive effect of properly selected probiot-
ics on gut microbiota and subsequently on prevention of 
LOS. However, this effect remains controversial in the light 
of the recent reviews. Zhang et al have stated recently that 
current evidence indicates that probiotic supplementation is 
safe and may significantly reduce the incidence of LOS in 
preterm neonates in NICU.11 Conversely, Olsen et al in their 
meta-analysis on prophylactic probiotics for preterm infants 
were unable to find significant reduction of sepsis rates, 
although they noticed a trend toward this effect.12 They found 
a significant reduction of NEC and a reduction in mortality 
in the neonates.
Probiotics, that is, lactobacilli and bifidobacteria, have 
been shown to significantly reduce the risk of NEC, all-cause 
mortality, LOS, and facilitate feed tolerance in preterm VLBW 
neonates. The mechanisms of benefits of probiotics include 
gut barrier enhancement, immune response modulation (eg, 
TLR4 receptor, nuclear factor-B, inflammatory cytokines), 
and direct inhibition of gut colonization by pathogens.19
It is postulated that correlation of distortions of the 
intestinal microbiota is a necessary first step to design novel 
microbiota-based screening approaches that might lead to 
early interventions to prevent LOS in high-risk infants.9 
Well-characterized and clinically proved probiotics can be 
used for this purpose.
As it is speculated on perspectives of the progress in 
managing serious infections in neonatology, clinical research 
offers the opportunity of adopting preventive strategies such 
as use of probiotics and lactoferrin to prevent LOS. How-
ever, these strategies remain to be commonly accepted and 
recommended.
Hypothesis
Our assumption is that probiotic bacteria administered 
directly after birth are beneficial for the development of 
intestinal microbiota and could prevent or significantly limit 
gastrointestinal colonization by pathogenic bacteria (PB) 
and development of abnormal microbiota. Permanent colo-
nization with probiotic bacteria in very early life improves 
gastrointestinal function in preterm neonates by reducing the 
onset of or decreasing the severity of the signs and symptoms 
of feeding intolerance and generalized bacterial infections, 
including sepsis and NEC.
Objectives
The aim of this study was to evaluate the safety of the tested 
probiotic preparation and its influence on the development 
of gut microbiota resembling those of healthy term-born, 
 
In
fe
ct
io
n 
an
d 
D
ru
g 
R
es
is
ta
nc
e 
do
w
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
18
8.
14
7.
37
.2
2 
on
 0
3-
A
pr
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Infection and Drug Resistance  2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1559
Effects of oral probiotic supplementation on gut Lactobacillus
breast-fed neonates, and on the clinical status of premature 
LBW neonates. More specific objectives were to determine 
whether colonization of the neonates gut by the tested pro-
biotic strains would influence populations of the potentially 
PB and reduce the incidence of sepsis and gastrointestinal 
disorders in these infants.
Trial design
This was a multicenter, randomized, double-blind, placebo-
controlled, and parallel-group study with two randomization 
arms (1:1). It was conducted in accordance with the original 
protocol PB-DM/SBK-NEC-01/11.
The amendment of inclusion criteria allowed for a higher 
birth weight (from up to 1,500 to 1,800 g), higher gestation 
age (from week 32 up to week 34), and longer study inclusion 
time (from up to 12 h to 48 h). The protocol was amended 
to account for differences in standard neonatal care at dif-
ferent study centers, especially in terms of the time of first 
feeding and insufficient recruitment. The abovementioned 
modifications were included in order to make the study group 
more homogeneous and increase recruitment rate. They were 
introduced following Independent Ethics Committee approval 
dated September 27, 2012.
Patients and methods
Patients
Eligible were preterm neonates of both sexes, born ≤34 weeks 
of gestation, and weighing ≥750 g and ≤1,800 g from adult 
mothers (aged ≥18 years). Children were enrolled by the 
investigators within 48 h after birth ready for enteral feeding.
Exclusion criteria were major congenital anomalies, 
including gastrointestinal abnormalities, which might 
 interfere with enteral nourishing, birth weight below 750 g 
or over 1,800 g, born >34 weeks of gestation, mother’s age 
<18 years, enteral nutrition contraindicated within the first 
48 h of life, birth asphyxia with Apgar score <4, severe 
clinical condition/disorder that the investigator considers as 
a contraindication (ie, including the presence of at least three 
out of four of the following symptoms: necessity of using 
mechanical ventilation and FiO
2
 >0.6 elevation to maintain 
blood oxygen saturation within the range of 88%–93%; 
metabolic acidosis, pH <7.20 and BE >[-10]; necessity of 
vasopressor agents to maintain proper arterial blood pressure; 
signs of failure to at least one vital organ [liver, kidneys, 
gastrointestinal tract, and adrenal glands]), administration of 
other probiotic preparations, enrollment in any other clinical 
study throughout the study period, and absence of parent/
legal guardian informed consent.
Ethics-approved written informed consent was obtained 
from the parents before enrolling a neonate in the trial.
The study took place between April 2012 and December 
2013 in eight NICUs in the whole area of Poland. The first 
participant was enrolled in the trial on July 07, 2012 and the 
last participant on July 10, 2013. The duration of subject’s 
participation was ~7 weeks, until they were withdrawn 
(according to withdrawal criteria) or until discharged from 
the hospital, whatever occurred earlier. The participant was 
administered the investigational product over the period of 
6 weeks and then observed for a further week.
Data were entered and stored in Microsoft Access and 
analyzed using JMPÒ software (version 7.0.1, SAS Institute 
Inc., Cary, NC, USA) and the R 9.2.1 software package (R 
Foundation for Statistical Computing).
Neonates were monitored in the cooperating centers, and 
appropriate care was given to them according to standards 
of medical care for neonates provided by Polish Society of 
Neonatology.13 LOS was defined according to criteria given 
by Gastmeier et al:14
•	 Presence of at least two of the following: temperature 
>38°C or <36.5°C or temperature instability, tachycar-
dia or bradycardia, apnea, prolonged capillary refill, 
metabolic acidosis, hypoglycemia, and other signs of 
bloodstream infections such as lethargy.
•	 Recognized pathogen cultured from one or more blood 
cultures or CoNS isolated from at least one blood culture 
or intravascular line and one of the following: C-reactive 
protein >2.0 mg/dL, immature/total neutrophil ratio 
(I/T ratio) >0.2, leukocytes <5,000/μL, and platelets 
<10,000/μL.
Interventions
Single dose of investigational product (probiotic or placebo) 
was administered orally twice daily with food (in the morn-
ing and in the evening). The first dose was administered 
within the first 48 h after birth and continued for 6 weeks or 
shorter, in case of earlier hospital discharge. Discontinuation 
of the enteral nutrition was equivalent with termination of 
the administration of the investigational product. Its intake 
could be discontinued for up to ≤7 days due to suspension of 
enteral feeding and no additional (supplementary) doses of 
the investigational product were administered. If the product 
intake was discontinued for more than 7 days, the patient was 
withdrawn from the study.
The tested probiotic was food for special medical 
purposes ( FFbaby® provided by the study sponsor, IBSS 
BIOMED S.A., Kraków, Poland) in the form of a powder 
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in glass vials. One dose contained not less than 106 CFU 
of a bacterial mixture including lyophilized Lactobacillus 
rhamnosus KL53A and Bifidobacterium breve PB04 and 
auxiliary substances: maltodextrin and ascorbic acid. Before 
administration, the tested product or placebo was diluted 
in 1.5 mL of milk (mother’s milk or infant formula) and 
administered enterally with a feeding tube or a teat (depend-
ing on the individual feeding method). The feed containing 
the tested product or placebo was prepared individually for 
each participant and used directly after preparation. The 
strains (L. rhamnosus KL53A and B. breve PB04) were well 
characterized in in vitro and in vivo studies using methods 
described elsewhere.13,14 The tested strains have documented 
human origin. They were isolated from the feces of a healthy 
breast-fed child and were selected from a larger strain 
collection because of their in vitro and in vivo probiotic 
properties. Their strong anti-inflammatory, antipathogenic 
activity, and tight-junctions stimulating properties were 
confirmed in laboratory studies. Safety, probiotic proper-
ties, and gut mucosa colonizing ability of the tested strains 
were checked on gnotobiotic (germ-free) mice and on rat 
neonates. The strains and their composition are subject to 
patent application.
The probiotic preparation was a composition of an active 
ingredient, that is, a mixture of L. rhamnosus KL53A and 
B. breve PB04 strains on maltodextrin as excipient and 
ascorbic acid as vehicle. Placebo was a composition of 
maltodextrin and ascorbic acid vehicle. It was produced 
under the same conditions as active product with the same 
appearance, net mass, and composition except for bacterial 
strains. The probiotic preparation and placebo were in the 
form of a lyophilized powder for suspension.
Microbiological examination of feces
Stool samples were collected before first administration of 
investigational product and then at 7-day intervals into two 
preweighted tubes containing liquid transport MRS medium 
(Oxoid Thermo Scientific, Basingstoke, UK) for probiotic 
strains and Schaedler Anaerobic Broth (Difco Labs, Detroit, 
MI, USA) for the remaining bacteria and delivered deep frozen 
(at –70°C) to the central laboratory. They were then thawed, 
serially diluted, and cultured on a series of appropriate differ-
ential media to measure bacterial populations of Lactobacillus 
and Bifidobacterium as well as representative potentially PB: 
Clostridium difficile, Staphylococcus aureus, Enterococcus 
spp., Klebsiella spp., and Escherichia coli. Following agar 
media were used: McConkey Agar (Oxoid, UK) for Enterobac-
teriaceae, Columbia Blood Agar (Difco, USA) with 5% sheep 
blood for staphylococci and streptococci, Enterococcosel Agar 
(BD-BBL, Franklin Lakes, NJ, USA) for enterococci, MRS 
(De man, Rogosa and Sharpe) agar (Oxoid) for lactobacilli and 
other lactic acid bacteria (LAB), BL Agar (Oxoid) for bifido-
bacteria, and Wilkins-Chalgren Agar Base with supplements 
for Clostridium. For Candida fungi, Sabouraud’s substrate 
Agar (Biocorp, Warsaw, PL, USA) was used. For detailed 
identification of species of fully formed colonies, phenotypic 
methods were used and especially API (bioMérieux) tests: API 
STREP (for Streptococcus and Enterococcus), API STAPH 
(for Staphylococcus), API 20E (for Enterobacteriaceae), API 
20A (for anaerobic bacteria), and API 50CH (for Lactobacil-
lus). The results were analyzed with API LAB software for 
classification of test bacteria.
Further identification of the isolated strains Lactobacil-
lus and Bifidobacterium genera was based on genotyping 
(polymerase chain reaction [PCR]) methods.21,22 The species-
specific PCR for L. rhamnosus was done using the following 
primers: PrI 5′ CAG ACT GAA AGT CTG ACG G 3′ and 
RhaII 5′ GCG ATG CGA ATT TCT ATT ATT 3′ which ampli-
fies a 190 bp fragment. The PCR conditions were as follows: 
one cycle at 92°C for 2 min; 30 cycles at 95°C for 30 s, at 
55°C for 30 s, at 72°C for 30 s; and one cycle at 72°C for 
1 min. The following primers IDB31F 5′ TAG GGA GCA 
AGG CAC TTT GTG T 3′ and IDBC1R 5′ ATC CGA ACT 
GAG ACC GGT T 3′ were used to identify B. breve. The 
size of the PCR product was 827 bp and the protocol was 
as follows: one cycle at 94°C for 5 min; 35 cycles at 94°C 
for 30 s, at 64°C for 40 s, at 72°C for 30 s; and one cycle at 
72°C for 5 min.
Molecular typing of isolates as belonging to strains 
contained in the product, that is, L. rhamnosus KL53A and 
B. breve PB04, was done using pulse-field gel electrophoresis. 
The examined isolates of L. rhamnosus were prepared accord-
ing to the procedure of Tynkkynen et al.15 Strains belonging 
to this species were digested with restriction enzyme SgsI 
(25 U/block) (Thermo Fisher Scientific, Waltham, MA, 
USA). Preparation of B. breve genomic DNA was performed 
according to Roy et al.16 In order to digest the chromosomal 
DNA of this species, we used SpeI restriction enzyme (25 U/
block) (Thermo Fisher Scientific).
Electrophoresis was done in CHEF-DR II apparatus 
(BioRad, Hercules, CA, USA) at the following separation 
conditions for L. rhamnosus: starting pulse 1 s, final pulse 
15 s, voltage 5 V/cm, the temperature was 14°C, and the 
running time was 22 h and for B. breve: starting pulse 1 s, 
final pulse 20 s, voltage 6 V/cm, temperature 14°C, and 
running time 18 h.
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Microbiological testing of blood
Diagnosis of sepsis was confirmed by positive blood culture 
performed according to routine procedures used by local 
microbiology laboratories in the cooperating clinical centers 
according to the standards.13 Blood was taken aseptically from 
all suspected sepsis cases and 1 mL samples were injected into 
an aerobic blood culture bottle (Bactec Plus 26 Aerobic; BD 
Microbiology Systems, Franklin Lakes, USA) and cultured on 
MacConkey agar, horse blood agar (at 37°C, each for 24 h), 
and Sabourand agar (at 37°C for 38 h). The isolates were 
characterized using biochemical tests, bioMerieux identifi-
cation kit API system (bioMerieux, Marcy l’Etoile, France).
Only in cases of positive blood cultures caused by gram-
positive rods, blood was plated additionally on MRS (Oxoid, 
UK) and TPY (Biocorp, Poland) medium for bacteria of the 
genera Lactobacillus and Bifidobacterium. After inocula-
tion, plates were incubated for 48 h at 37°C under aerobic 
and anaerobic conditions. All strains of bacteria cultured on 
MRS and TPY agar were collected in the cooperating centers 
and were transferred to the central laboratory for molecular 
identification and typing to compare them with the strains 
included in tested probiotic.
Outcomes
Primary outcome measures
•	 Gastrointestinal tract colonization assessed weekly (day 1, 
7, 14, 21, 28, 35, 42, and 49) within 8 weeks. Bacteriologi-
cal tests involved quantitative and qualitative assessments 
of neonatal gut microbiota during clinical follow-up. 
Density of the bacterial populations of Lactobacillus and 
Bifidobacterium as well as following potentially PB and 
fungi were assessed: E. coli, Klebsiella sp., Clostridium 
sp., S. aureus including MRSA, S. epidermidis includ-
ing MRSE, Staphylococcus haemolyticus, Enterococcus 
faecalis, Streptococcus agalactiae, S. pyogenes, and 
Candida albicans. Stool samples were collected at 7-day 
intervals (±2 days) in the period of investigational product 
intake and on day 7 (±2 days) after the last dose of the 
investigational product. The first sample was collected 
before administration of the first dose of investigational 
product.
•	 Feeding intolerance episodes, including gastric residuals, 
vomiting, regurgitation of food, abdominal distension, 
abdominal rigidity, and gut motility disorders were 
assessed on a daily basis (from day 1 to 42 and on day 
49). Clinical parameters were evaluated throughout 
the period of care according to standard neonatal care 
procedures.
•	 Incidence and type of adverse events and serious adverse 
events (SAE) with special regard to sepsis caused by 
bacteria included in investigational product, assessed on a 
daily basis. Safety was evaluated by determining whether 
investigational product increases the incidence and influ-
ences the type of adverse events and SAE compared to 
placebo.
Main secondary outcome measures
•	 LOS caused by gram-positive or gram-negative bacteria 
assessed on a daily basis (from day 1 to 42 and on day 49). 
Sepsis was confirmed by positive blood cultures. Clinical 
parameters were evaluated throughout the period of care 
according to standard neonatal care procedures.
•	 NEC incidence, intensity, and severity assessed on a 
daily basis. Severity of neonatal NEC was determined 
according to Bell’s staging criteria.17 Clinical parameters 
were evaluated throughout the period of care according 
to standard neonatal care procedures.
•	 Mortality rate, with a focus on deaths attributed to NEC 
and sepsis assessed on a daily basis. Clinical parameters 
were evaluated throughout the period of care according 
to standard neonatal care procedures.
Sample size
As indicated in literature18 and information obtained from the 
study Medical Expert, the likelihood of the studied symptoms 
development in the control group is estimated at p
placebo
=0.3. 
On the assumption that the probiotic efficacy is 30%, the 
likelihood of symptoms development in the probiotic group is 
estimated at p
intervention
=0.21. Thus, the least significant sample 
size was calculated as 138 participants (69 participants per 
each group).
This sample size refers to participants who completed 
the entire clinical study cycle; it was therefore necessary 
to increase the number of participants to prevent random 
discontinuations from reducing the analyzed sample size 
below the determined level. In consideration of the likelihood 
of early patient withdrawal, the baseline sample size was 
increased by ca. 40%, that is, maximum of 194 participants 
were planned to be enrolled.
Randomization, allocation, concealment, 
implementation, and blinding
Participants were enrolled and randomly assigned to one 
of two study arms (probiotic or placebo) using equal group 
ratios, according to a computer-generated sequence (R soft-
ware package). The randomization list was produced by a 
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statistician with no clinical input in the trial and held securely 
by the study sponsor. Each study center received randomiza-
tion datasets (sets of randomization numbers to be assigned 
to study participants) and a set of packages containing the 
investigational products (probiotic or placebo), labeled with 
numerical codes assigned to one of the two treatment groups 
and a letter (A, B, C, or D). Each participant was assigned 
an ID number composed of a two-digit study center number 
and a three-digit screening number assigned in chronological 
order as participants were enrolled in a given center. Upon 
randomization, the participant’s ID was supplemented with 
a three-digit randomization number and a letter (A–D) iden-
tifying the randomization data set.
The participants, investigators, clinic and central labora-
tory staff, study monitors, persons entering data to a database, 
and study statisticians were blinded to group assignment.
Statistical methods
Participants were described by means of morphometric and 
developmental parameters, such as birth weight, body weight 
gain, and gestational age (weeks of gestation). Experimental 
data were described using descriptive statistical methods. 
For continuous variables, parameters describing the central 
tendencies (mean with the standard error, median, and modal 
value) and dispersion parameters: SD, minimum, maximum, 
and quartile limits were presented. For categorical variables, 
fractions of cases were determined when the variables have 
specific values. Inductive statistical tools were used to com-
pare study groups, depending on the type and distribution 
of the analyzed variables. Quantitative variables for the two 
groups were compared with the Student’s t-test. For variable 
distribution significantly deviating from the Gaussian curve, 
the Student’s t-test was substituted with nonparametric tests 
(Mann–Whitney, Kolmogorov–Smirnov, or Wilcoxon’s tests) 
due to method limitations. For comparisons of more than two 
groups, analysis of variance (ANOVA) and post hoc (a poste-
riori) Tukey’s and Dunnett’s tests were applied. For variables 
noncompliant with the assumptions of the ANOVA (such 
as normal distribution and uniformity of variance groups), 
it was substituted with a nonparametric equivalent of the 
Kruskal–Wallis test supplemented with the Steel-Dwass test, 
a nonparametric equivalent of the post hoc Tukey test. The 
analysis of categorized variables was based on comparisons 
between the fractions of values of such variables. These 
analyses were carried out with frequency tests χ2 (chi-square) 
or G2 (likelihood ratio). The significance level for statistical 
analysis was set at p<0.05. The following statistical tools were 
used: SAS JMP 7.0.1 and R package 9.2.1.
Ethics and trial approval
This trial received ethical approval from the Independent 
Ethics Committee of Jagiellonian University, Krakow, 
Poland (no. KBET/127/L/2012 on April 26, 2012) and was 
conducted according to good clinical practice requirements 
and the Declaration of Helsinki.
This clinical study has been entered into the clinical 
trials register retrospectively due to the fact that clinical 
trials regarding food products are not subject to regulatory 
approval and there is no legal obligation to include such tri-
als in the register. But, in order to fulfill journal policies, we 
have obtained needed registration in ClinicalTrials.gov no. 
NCT02073214.
Results
Altogether 182 participants were enrolled and randomized; 
one child did not receive investigational product. Four out of 
181 were excluded from the analysis due to formal reasons 
such as incorrect qualification.
For statistical analyses, the following populations were 
distinguished:
1. Baseline characteristics for all study participants enrolled, 
who provided written informed consent (n=177).
2. Intent-to-treat (ITT) group: participants who were 
randomized and used at least one capsule of the inves-
tigated product or placebo (n=177). Safety analysis was 
performed for this population.
3. Per-protocol (PP) group: participants who completed the 
study according to the protocol and have not fulfilled any 
of the exclusion criteria throughout the study (n=153). 
Efficacy analysis, including additional analysis, was car-
ried out for this population. Figure 1 presents a diagram 
of participant flow.
Maternal and neonatal baseline characteristics are 
presented in Table 1. In general, no significant differences 
between groups were found. The only significant differ-
ences regarding mother’s age and baby head circumfer-
ence were found when characteristics of probiotic group 
(AB) and placebo group (CD) neonates were compared. 
Mean values of the age of mother and head circumference, 
however, seem to have no influence on the interpretation 
of obtained results and the statistical significance found 
results from large data set. It is thus worth stressing that 
due to randomized allocation of participants to study and 
control group, it was possible to achieve great similarity 
of the analyzed groups of participants, which validates 
further statistical comparisons.
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Efficacy evaluation
Gastrointestinal tract colonization (primary 
outcome)
There were no significant differences between probiotic (AB) 
and placebo (CD) groups regarding numbers of  Lactobacillus 
and Bifidobacterium found in the first collected sample, that 
is, sample collected before intervention. There were, how-
ever, significant differences between groups in favor to AB 
group in Lactobacillus counts, in the samples collected from 
weeks 2 to 7 of the study (Figure 2). The differences related 
Figure 1 Participant flow chart.
Notes: *According to the protocol, participant could have been withdrawn from the trail due to more than one reason.
Assesed for eligibility (n=182)Enrollment
Randomized (n=181)
Safety assesment (n=177)
Intent-to-treat group (ITT)
Allocation
Follow-Up
Analysis
Efficacy assessment (n=153)
Per-protocol group (PP)
Excluded (n=1)
Not meeting inclusion criteria (n=0)
Allocated to intervention (n=91)
Placebo
Received allocated intervention (n=88)
Did not receive allocated intervention (formal errors) (n=3)
Received allocated intervention (n=73)
Did not receive allocated intervention* (n=15):
Informed consent withdrawal (n=1)
Discontinuation of the investigational product for
more than 7 days (n=2)
Severe intracranial haemorrhage (Ill or IV degree)
(n=3)
Severe clinical condition withdrawal from the study
(n=2)
Early onset sepsis (n=3)
Patient transfer to another hospital (n=3)
Administration of other probiotic (n=3)
Occurrence of a serious adverse event (n=4)
Allocated to intervention (n=88)Allocated to intervention (n=89)
Received allocated intervention (n=80)
Did not receive allocated intervention* (n=9):
Gastrointestinal abnormalities or disorders during
hospitalization (n=3)
Discontinuation of the investigational product for
more than 7 days (n=6)
Severe intracranial haemorrhage (Ill or IV degree)
(n=1)
Severe clinical condition withdrawal from the study
(n=2)
Occurrence of a serious adverse event (n=3)
Necessity of surgical abdominal intervention (n=1)
Administration of other probiotic (n=1)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0)
Analyzed (n=80)
Excluded from analysis (give reasons) (n=0)
 Analyzed (n=73)
Excluded from analysis (give reasons) (n=0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) (n=0)
Other (n=2)
Allocated to intervention (n=90)
Probiotic
Received allocated intervention (n=89)
Did not receive allocated intervention (formal errors) (n=1)
Declined to participate (n=0)
Other reasons (n=1)
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to Bifidobacterium counts appeared significant in weeks 2 
and 3 (Figure 3).
The stool samples analysis revealed that probiotic 
supplementation was associated with significantly higher 
populations expressed in percentages of L. rhamnosus and 
B. breve versus other cultivable bacteria, and especially 
potentially pathogenic ones in the gut microbiota comparing 
to the placebo group, predominantly in the first weeks of life 
( Figure 4). Effectiveness of the colonization was also mea-
sured by the number of participants in each group colonized 
by L. rhamnosus and B. breve. We have also analyzed the last 
available sample taking into account that some participants 
were discharged earlier from the hospital (Table 2).
Molecular typing of all isolates belonging to species 
L. rhamnosus and/or B. breve obtained from feces revealed 
that nearly all (98%) neonates from study group were 
colonized with L. rhamnosus KL53A and nearly the same 
proportion (94%) with B. breve PB04. A very high propor-
tion of the neonates (91%) were colonized with both strains 
throughout the study period (Figure 5).
There were no significant differences between groups in 
the abundance of potentially PB (Clostridium spp.,  E. coli, 
Table 1 Maternal and neonatal baseline characteristics
Feature Probiotic Placebo Total p value
Sex
Female 52.81% (47) 43.18% (38) 48.02% (85) 0.1996a
Male 47.19% (42) 56.82% (50) 51.98% (92)
Mode of delivery
Cesarean 84.27% (75) 87.50% (77) 85.88% (152) 0.5368a
Natural 15.73% (14) 12.50% (11) 14.12% (25)
Multiple pregnancy
No 71.91% (64) 68.18% (60) 70.06% (124) 0.4523a
Twins 28.09% (25) 30.68% (27) 29.38% (52)
Triplets 0.00% (0) 1.14% (1) 0.56% (1)
Mother’s perinatal antibiotic treatment
No 44.94% (40) 56.82% (50) 50.85% (90) 0.1137a
Yes 55.06% (49) 43.18% (38) 49.15% (87)
Baby’s antibiotic treatment, before first administration of the investigational product
No 17.98% (16) 12.50% (11) 15.25% (27) 0.3096a
Yes 82.02% (73) 87.50% (77) 84.75% (150)
Apgar score
4 1.14% (1) 1.14% (1) 1.14% (2) 0.5708a
5 7.95% (7) 5.68% (5) 6.82% (12)
6 17.05% (15) 12.50% (11) 14.77% (26)
7 20.45% (18) 29.55% (26) 25.00% (44)
8 32.95% (29) 29.55% (26) 31.25% (55)
9 11.36% (10) 6.82% (6) 9.09% (16)
10 9.09% (8) 14.77% (13) 11.93% (21)
Mother’s age
N 89 88 177 0.0297b
Av (±SD) 29.24 (±5.61) 31.09 (±5.64) 30.16(±5.69)
Gestational age (weeks)
N 89 88 177 0.9457c
Av (±SD) 29.73 (±2.26) 29.67 (±2.32) 29.70 (±2.28)
Birth weight
N 89 88 177 0.1175c
Av (±SD) 1281.24 
(±281.18)
1350.11 
(±292.18)
1350.11 
(±292.18)
Body length
N 89 88 177 0.1663c
Av (±SD) 40.57 (±3.94) 41.27 (±4.29) 40.92 (±4.12)
Head circumference
N 89 88 177 0.0280c
Av (±SD) 26.99 (±2.20) 27.79 (±1.95) 27.39 (±2.11)
Notes: aChi-square test; bStudent’s t-test; cMann–Whitney U-test.
Abbreviations: SD, standard deviation; Av, arithmetical mean.
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C. albicans, Klebsiella spp., Enterobacter spp., S. aureus 
 including MRSA, S. epidermidis) present in consecutive 
samplings.
Additional analysis was performed based on percentage 
of participants, for whom the following parameters were 
found in subsequent samplings of their feces: i) presence of 
the Lactobacillus or Bifidobacterium (LAB) genera regarded 
as representatives of the normal and favorable members of 
the gut microbiota without coincidental presence of the above 
listed potentially PB; ii) presence of only potentially PB, with-
out Lactobacillus and Bifidobacterium; iii) presence of both 
groups of microbes, that is, Lactobacillus, Bifidobacterium, 
and potentially PB in feces (MF); and iv) absence of the cul-
tivable microorganisms. We found that the percentage of the 
infants with only PB decreased and the percentage of those 
with MF increased in subsequent samplings. In the first sam-
pling (1), the percentage of the neonates with only PB only 
was greater in the probiotic group than in the placebo group. 
In the next sampling (2), an increase of the percentage of the 
neonates with MF was observed in the probiotic group and 
the percentage of infants with PB increased over three times 
in the placebo group. In subsequent samplings, it was found 
that the percentage of the patients with PB was decreased, 
whereas the percentage of those with MF increased. These 
changes were more pronounced in the probiotic group than 
in the placebo group. However, no statistical significance 
Figure 2 Lactobacillus count found in subsequent samplings in the probiotic group (green) and placebo group (red), transformed into logarithms.
Notes: The chart shows median values, quartile intervals, range, and outliers determined using American Analyst Society methods. **p<0.01; ***p<0.001.
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Figure 3 Bifidobacterium count found in subsequent samplings in the probiotic group (green) and placebo group (red), transformed into logarithms.
Notes: The chart shows median values, quartile intervals, range, and outliers determined using American Analyst Society methods. *p<0.05; ***p<0.001.
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between was found between the compared groups as tested 
by Cochran–Mantel–Haenszel test. The results are shown 
in Figure 6.
Feeding intolerance episodes (primary outcome)
There was no difference in the number of feeding intolerance 
episodes, such as gastric residuals, vomiting, regurgitation 
of food, abdominal distension, abdominal rigidity, and gut 
motility disorders in the groups.
LOS (secondary outcome)
Overall sepsis analysis in terms of safety was performed on 
intent to treat group and has been presented in Safety evaluation 
section while more detailed analysis was performed on a PP 
group. In this population, there were 18 episodes of late-onset 
gram-positive sepsis in 18 participants including 11 in the 
probiotic group (13.8%) and 7 in the placebo group (9.6%). 
Staphylococci were dominant etiological agents of the late-
onset gram-positive sepsis (16 episodes), whereas the remaining 
Figure 4 Percentage participation of L. rhamnosus and B. breve in the total cultivable part of the fecal microbiota of neonates from probiotic (green) group versus placebo 
(red) group. 
Notes: The chart shows median values, quartile intervals, range, and outliers determined using American Analyst Society methods. *p<0.05; **p<0.01; ***p<0.001; ~ Means 
around the significance threshold 0.0750>p>0.05.
Abbreviations: L. rhamnosus, Lactobacillus rhamnosus; B. breve, Bifidobacterium breve.
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Table 2 Number of participants colonized (C) or not colonized (NC) by Lactobacillus rhamnosus (LR) and Bifidobacterium breve (BB) in 
individual samplings and significance levels of differences for comparisons between groups (p)
Sampling number Colonized 
with
Probiotic group Placebo group p
NC C NC C
1 LR 79 1 72 1 0.9480
BB 79 1 71 2 0.5068
2 LR 33 46 62 10 <0.0001
BB 51 58 67 5 <0.0001
3 LR 27 51 56 16 <0.0001
BB 40 38 55 17 <0.0001
4 LR 22 51 54 15 <0.0001
BB 35 38 41 28 0.1706
5 LR 18 45 45 14 <0.0001
BB 19 44 31 28 0.0120
6 LR 15 39 32 12 <0.0001
BB 17 37 23 21 0.0373
7 LR 13 31 19 14 0.0135
BB 11 33 10 23 0.6051
8 LR 19 18 9 17 0.1881
BB 8 29 11 15 0.0782
Last available sampling for 
participant
LR 27 53 43 30 0.0018
BB 21 59 34 39 0.0089
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sepsis episodes were associated with Klebsiella pneumoniae (1 
episode) and yet not identified bacteria (1 episode).
We did not show significant differences between groups 
in sepsis incidence. Also, analysis of late-onset gram-positive 
sepsis occurrence in probiotic and placebo groups that 
involved the difference in the participation of the infants 
belonging to these groups on individual days of the study, 
the number of episodes over weeks of the study, and inci-
dence of sepsis diagnosis regardless of the day of stay did 
not reveal statistically significant differences between the 
groups. Similarly, probiotic-to-placebo group comparisons 
did not yield statistically significant increase of risk both in 
the case of analysis of the whole period of the study and for 
risk over subsequent weeks when subsequent confounders 
were involved. Risk analysis (HR) of the first episode of 
late-onset gram-positive sepsis in the probiotic-to-placebo 
group comparison did not yield statistically significant results 
as well. There were also no differences between groups in 
the occurrence of late-onset gram-negative sepsis. It was 
diagnosed in total in one baby in the probiotic group and 
none in the placebo group.
Additional analysis has revealed that regardless of 
the assignment to either of the study groups (probiotic or 
placebo), B. breve colonization correlated with the lower 
staphylococcal sepsis incidence (Figure 7). The prob-
ability of sepsis occurrence in a given week and the next 
week was significantly lower in participants colonized by 
B. breve than in not colonized participants. Participants 
without sepsis had significantly higher count of bacteria of 
Lactobacillus and Bifidobacterium genera in the week in 
which sepsis was diagnosed (H=8.4150; df=3; p=0.0382). 
The same dependence was observed for all Bifidobacterium 
(H=18.6466; df=3; p=0.0003) and B. breve (H=9.5991; df=3; 
p=0.0223). However, it was not found for Lactobacillus 
(H=1.0521; df=3; p=0.8787) and L. rhamnosus (H=1.3038; 
df=3; p=0.7282). When L. rhamnosus and B. breve were 
considered together, the dependence was close to significance 
threshold (H=6.7444, df=3, p=0.0805). Moreover, we have 
also found that the number of days with sepsis symptoms was 
significantly smaller in participants who were colonized by 
L. rhamnosus and B. breve prior to the next stool collection 
than in noncolonized participants.
Necrotizing enterocolitis (secondary outcome)
There were no statistically significant differences found 
between groups neither when the total incidence of NEC over 
the whole period of the was analyzed nor when numbers of 
episodes in both groups were analyzed. Logistic regression 
models were calculated to estimate the risk (OR) of NEC 
in the period of the study. Results were not statistically sig-
nificant in the univariate model and after standardization to 
account for the type of milk the baby was fed, mother’s age 
and baby head circumference, and additionally body weight 
at birth. No statistically significant results were found when 
individual subperiods of the study were analyzed.
Altogether there were six episodes of NEC, found in five 
participants: five in the probiotic group and one in the placebo 
group. In the probiotic group, two participants developed 
NEC of I degree, one participant developed twice NEC of II 
degree and one participant developed NEC of III degree. In 
the placebo group, NEC of II degree was diagnosed.
Mortality (secondary outcome)
Mortality rate, in particular deaths attributed to NEC and 
sepsis, did not reveal differences between the groups. More 
in-depth analysis of mortality over individual weeks of 
the study did not show statistically significant differences 
either. During the 49-day period of the study, six deaths 
in total were noted, which results in 3.39% mortality rate 
in the study group. There were two deaths in the probiotic 
group (mortality rate for this group was 2.25%) and four in 
the placebo group (mortality rate 4.55%). In the probiotic 
group, the causes of deaths were intracerebral hemorrhage 
of III degree, bilateral and intracerebral hemorrhage in cer-
ebellum in one participant and NEC in one participant. In 
the placebo group, the causes of deaths were intraventricu-
lar hemorrhage of III and IV degrees in two participants, 
malformation syndrome in one participant and sepsis with 
septic shock and disseminated intravascular coagulation in 
one participant. Sepsis caused one death in total, it was a 
LOS in the placebo group.
Figure 5 Percentage of neonates colonized by L. rhamnosus KL53A and B. breve 
PB04 strains (PP population, probiotic group, n = 80).
Abbreviations: L. rhamnosus, Lactobacillus rhamnosus; B. breve, Bifidobacterium breve; 
PP, perprotocol.
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Safety evaluation (primary outcome)
Safety evaluation was based on the assessment of the num-
ber and types of adverse events and SAE in all enrolled 
participants who were administered at least one dose of the 
investigational product (ITT group, n=177). It should be 
also noted that adverse events related to feeding intolerance 
were analyzed as primary end point and so were excluded 
from safety analysis. The results are provided in the Efficacy 
section. The most often observed adverse event was apnea, 
observed in 43% participants in total. Subsequent adverse 
events were intraventricular hemorrhage (33%), anemia 
(19%), respiratory disorders (17.5%), pneumonia (13%), 
desaturation (12%), conjunctivitis (9%), infection (8.5%), 
retinopathy (8.5%), patent ductus arteriosus (8%), jaundice 
Figure 6 Percentage of participants colonized with bacteria representing normal gut microbiota compared with those colonized with potentially pathogenic bacteria or with 
both types of microbes or no bacteria or fungi during the course of the study. (A) Probiotic group; (B) placebo group.
Notes: LA – normal microbiota: Lactobacillus and Bifidobacterium (blue). PB – potentially pathogenic bacteria and fungi: Clostridium spp., Escherichia coli, Candida albicans, 
Klebsiella spp., Enterobacter spp., Staphylococcus aureus including MRSA, and Staphylococcus epidermidis including MRSE (red). MF – mixed flora (green). No flora – no bacteria 
or fungi present (yellow).
Abbreviations: MRSE, methicillin-resistant S. epidermidis; MRSA, methicillin-resistant S. aureus..
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(6%), neonatal pneumonia (5.65%), hyponatremia (5%), 
early onset sepsis (5%), tachycardia (4.5%), skin injury 
(4.5%), hyperglycemia (4%), edema (4%), respiratory 
disorders (4%), bronchopulmonary dysplasia (3.4%), and 
others (with lesser incidence). No statistically significant dif-
ferences in incidence of adverse events between groups AB 
(probiotic) and CD (placebo) were found with the exception 
of hypocalcemia which occurred statistically more often in 
the CD group (0.0% vs 3.4%; p=0.0394). Hypocalcemia was 
deemed by the investigator as not related to administration of 
the investigational product in all reported episodes. Numbers 
of adverse events of specific types in individual study groups 
were also compared. The analysis did not reveal any statisti-
cally significant differences except conjunctivitis, of which 
a greater share of babies in the AB group had two episodes 
diagnosed compared with the CD group (three in seven babies 
in the AB group with conjunctivitis, zero in nine babies in 
the CD group with conjunctivitis, p=0.0153). All reported 
episodes of conjunctivitis were classified by the investigator 
as not related to administration of the investigational product.
Altogether 565 adverse events were reported during the 
study in total (excluding feeding intolerance episodes and 
SAE); 278 and 287 in groups AB and CD, respectively, 
the investigators qualified 520 of them as not to be related 
to the investigational product (255 and 265 in groups AB 
and CD, respectively) and 45 was considered unlikely (23 
and 22 in groups AB and CD, respectively). There were no 
adverse events assessed as probably or certainly related to 
the investigational product.
SAE occurred in 40 participants (22.6%). The most often 
was LOS, there were altogether 27 episodes that occurred in 
24 participants (13.6%) (ITT group). Differences between 
groups were not statistically significant. Gram-positive 
sepsis was diagnosed in 20 cases (20 participants) and gram-
negative sepsis in 6 cases (4 participants). LOS was the cause 
of one death which occurred in placebo group. Other SAE 
were: intraventricular hemorrhage (3.4% of participants), 
death (3.4%), NEC (2.8%), pneumothorax (1.7%), early onset 
sepsis (1.7%), leukomalacia (1.1%), pneumonia (1.1%), 
bronchopulmonary dysplasia (0.6%), circulatory deficiency 
(0.6%), respiratory deficiency (0.6%), multiorgan dysfunc-
tion (0.6%), and intestinal perforation (0.6%). There were 
no statistically significant differences between the groups. 
From among all 61 reported SAE, suspected relation to 
administration of the investigational product was assessed 
for 3 events in the probiotic group (two events – NEC, one 
event – death neonatal) (Table 3). No relation was suspected 
for 58 events (33 in probiotic group and 25 in the placebo). It 
is worth to stress that no sepsis was caused by Lactobacillus 
or Bifidobacterium.
Overall safety analysis confirmed that probiotic including 
L. rhamnosus KL53A and B. breve PB04 may be safely used 
in preterm, LBW neonates.
Discussion
This study showing inverse relationship between colonization 
of the preterm neonates gut by bifidobacteria and staphylo-
coccal sepsis rates indicates that probiotics can influence 
generalized infections such as sepsis.18,19 This relationship 
was demonstrated for both study and control groups taken 
Figure 7 Correlation between B. breve gut numbers and staphylococcal sepsis 
(Observed in both groups).
Abbreviations: B. breve, Bifidobacterium breve.
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Table 3 Number of SAE except for sepsis and NEC in probiotic 
and placebo groups – ITT group
SAE Probiotic  
group
Placebo  
group
Bronchopulmonary dysplasia 1 0
Periventricular leukomalacia 1 2
Cardiovascular insufficiency 0 1
Neonatal respiratory failure 0 1
Neonatal multiorgan failure 0 1
Pneumothorax 1 1
Neonatal intestinal perforation 1 0
Early onset neonatal sepsis 0 3
Sepsis neonatal/disseminated intravascular 
coagulation in newborn
0 1
Intraventricular hemorrhage neonatal 3 3
Respiratory tract hemorrhage neonatal 1 0
Neonatal pneumonia 1 1
Death neonatal 2 4
Abbreviations: SAE, serious adverse events; NEC, necrotizing enterocolitis; ITT, 
Intent-to-treat.
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together and obtained results seem to be an important obser-
vation indicating that probiotic use in the group of LBW 
neonates may decrease staphylococcal sepsis rates. Since 
the clinical effects of probiotics are strain dependent, the 
probiotic strains applied by us were selected from a larger 
strain collection of documented human origin because of 
their in vitro and in vivo characteristics indicating their strong 
anti-inflammatory activity, ability to exclude PB from their 
adherent sites on human enterocytes, and tight-junctions 
stimulating properties for these cells (unpublished). Safety, 
probiotic properties and colonizing ability of the tested 
strains were checked on gnotobiotic (germ-free) mice and 
on rat neonatal models.
Efficacy of probiotics in preventing sepsis in LBW neo-
nates remains controversial. The meta-analysis published 
by Zhang et al has indicated that probiotics may decrease 
neonatal sepsis rates at NICU.11 However, another recent 
meta-analysis performed by Olsen et al on prophylactic 
usage of probiotics for LBW neonates, based on 12 studies, 
states that probiotic supplementation is related to significant 
decrease of NEC but not to sepsis rates.12 It is of interest 
why these two species were not used in the studies analyzed 
by Olsen et al. As mentioned before, it is known that each 
probiotic strain and a mixture of different probiotics is indi-
vidual and thus results from other even very similar studies 
cannot be extrapolated.20 Another explanation which can be 
offered here is that sepsis occurrence was monitored in only 
7 of all clinical trials analyzed by Olsen et al, which might 
result in making analysis of a population of the neonates too 
small to reach significance of the differences between study 
versus control groups. The authors mentioned in discussion 
of their meta-analysis that they observed a trend toward a 
benefit in the reduction of sepsis. Most probably, this trend 
could be converted into significance, if the authors of the 
trials, in which B. breve was used, should break their data 
according to the pathogens causing sepsis and concentrate 
over staphylococci as most common cause of the neonatal 
sepsis. Our data indicate that a high abundance of B. breve 
in the gut microbiota is related to lower rates of sepsis in 
LBW neonates. The only possibility to increase numbers 
of bifidobacteria in the neonates is to supply them orally in 
a form of a probiotic preparation. It seems that the crucial 
factor enabling successful gut colonization by these bacteria, 
not mentioned in protocols of the studies analyzed by Olsen 
et al, is a time of starting digestive tract colonization by 
probiotics. Gut of the infants treated in NICU is very rapidly 
colonized with the hospital pathogens; thus, probiotics should 
be given shortly after exposition of the infants to hospital 
environment. Their chances of probiotic bacteria to overcome 
commensal bacteria when they have already colonized the 
gut are very limited.
Colonization with probiotic strains given to neonates 
appeared to be highly efficacious as nearly all of them showed 
a presence of both probiotic strains in their feces. This effect 
may also explain general improvement of the gut microbiota 
composition with predominance of lactobacilli and bifido-
bacteria over other microbes.
Here, we cannot offer explanation why only sepsis caused 
by CoNS but not Proteobacteria, that is, gram-negative rods 
has been influenced by the given probiotic mixture, although 
gram-negative bacteria appeared to be more susceptible to 
inhibitory activities of the used probiotics in vitro. However, 
this is just reflection of the higher numbers of the neonates 
with sepsis caused by staphylococci. In our study, numbers 
of the cases of gram-negative sepsis were too low to achieve 
statistical significance.
Loss of gut barrier function is considered as a primary 
mechanism of sepsis caused by gram-negative bacteria in 
VLBW and LBW neonates treated at NICU. It has been dem-
onstrated that the bacteria translocate through gut wall, reach 
bloodstream either directly by invading submucosal capillary 
vessels or indirectly by Peyer’s patches and lymphatics to blood 
and cause bacteremia and then sepsis. There are only a few 
publications showing that also gram-positive cocci have been 
able to translocate through inadequately tight GI tract mucosa 
in critically ill adult patients treated at ICU. No direct studies 
on translocation of staphylococci from gut into bloodstream in 
premature neonates were yet published. However, a regulation 
of intestinal permeability functions by probiotics as a preven-
tive measure for both chronic and acute inflammations of the 
digestive tract are recently postulated.7 Both L. rhamnosus 
KL53A and B. breve PB04 used in this study have been shown 
as potent stimulators of the tight junction proteins by in vitro 
cultured enterocytes (unpublished). It is therefore possible that 
at least one of the mechanisms by which probiotics interfere 
with postulated translocation of staphylococci from gut is 
based on restoration of the gut barrier functions.
Conclusion
Orally administered, new probiotic preparation containing a 
mixture of L. rhamnosus KL53A and B. breve PB04 to pre-
term, LBW neonates is safe and effectively colonizes their 
distorted gut microbiota and it may also contribute to lower 
staphylococcal sepsis rates.
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